Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol

Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol

Introduction Up to 50% of soft tissue sarcoma (STS) patients develop metastases in the course of their disease. Cytotoxic therapy is a standard treatment in this setting but yields average tumour response rates of 25% at first line and ≤10% at later lines. In oligometastatic stage, stereotactic body...

Full description

Bibliographic Details
Main Authors: Nicolas Penel, Dominique Vaur, Juliette Thariat, Alexandre Escande, Jennifer le Guevelou, Colin Debaigt, Esma Saada-Bouzid, Julien Viotti, Nazim Khalladi, David Thibouw, Marie Pierre Sunyach, Laurence Moureau-Zabotto, Mohamed Benchalal, Ovidiu Veresezan, Anne Ducassou, Cecile le Pechoux, Maria Jolnerovski, Celine Bazille, Raphael Serre, Christine Lovera
Format: Article
Language:English
Published: BMJ Publishing Group 2020-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/9/e038391.full

Internet

https://bmjopen.bmj.com/content/10/9/e038391.full

Similar Items